Other studies have shown that activation of the PPARα–FGF21 pathway has protective effects against lipid accumulation and NAFLD and NASH development (Marino et al., 2016; Zeng et al., 2017). The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.